Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL
TORONTO--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the approval of Clareon ® PanOptix ® Pro intraocular lens (IOL) for cataract patients in Canada. PanOptix Pro leverages proprietary ENLIGHTEN ® NXT Optical technology which delivers the lowest light scatter and highest reported light utilization of any trifocal IOL. 1-3,5-9,**,‡‡ PanOptix Pro provides an unprecedented 94% light utilization, compared to a theoretical maximum utilization of 96% for diffractive optics. 1-4,*,**,† These enhancements also provide more uninterrupted light distribution from distance to near, and a 16% increase in optical image contrast between distance and intermediate. 1,††,‡ PanOptix Pro builds on the clinically-proven low visual disturbance profile, high spectacle independence and exceptionally high patient satisfaction of PanOptix. 10-13,§,§§,¶,¶¶
"Now, with PanOptix Pro, more light utilization and less light scatter is possible‡,‡‡, empowering both my practice and my patients.'
Share
'As the global leader in eye care, we are committed to improving our technologies to advance patient outcomes through rigorous, world-class R&D,' said Rob Scott, VP, Intraocular Devices, R&D, Alcon. 'Our team looked at hundreds of design options, ultimately landing on a targeted diffractive refinement that helped us recover 50% of light lost to scatter, and reposition it to a beneficial focal point for PanOptix Pro. 1,3,10.14-19,* This allowed for specific enhancements while maintaining the features that have driven the success of PanOptix—the world's most implanted trifocal IOL.' 1-3,20,21,*,**,‡‡,‖,Ω
'PanOptix has been a cornerstone of my cataract practice for eight years,' said Dr. Rosa Braga-Mele, MD, MEd, FRCSC, Professor of Ophthalmology, University of Toronto. 'These lenses have consistently delivered outstanding visual outcomes for my patients 10, 24, § – a low visual disturbance profile 25, ∂ and a happy patient with greater spectacle independence. 23, § So, it's exciting to see this technology evolve to further meet patients' visual expectations. Now, with PanOptix Pro, more light utilization and less light scatter is possible ‡,‡‡, empowering both my practice and my patients.'
PanOptix Pro will be available in Canada from Alcon in the single-use Clareon AutonoMe ® preloaded delivery system and as well as with the Clareon Monarch ® IV delivery system in early 2026. 22 PanOptix Pro offers a +2.17 diopter intermediate and a +3.25 diopter near add power. Like all Alcon IOLs, PanOptix Pro will be available with blue light and ultraviolet filtering. 22
For surgeons interested in more information on PanOptix Pro, please speak to a local Alcon representative.
About Clareon PanOptix Pro
The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Please consult the Directions for Use regarding indications, precautions, cautions and warnings which is available at ifu.alcon.com.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.ca.
* PanOptix has 88% light utilization (12% scatter light)/PanOptix Pro 94% light utilization (6% scatter light).
** Based on manufacturer-reported values and respective methodology for Clareon PanOptix, Envista Envy, AT Elana, Gemetric and Rayner.
† For feasible diffractive optics of up to pentafocal design from Krackhardt et al.
†† Simulated photopic through-focus point spread function (light intensity [energy])—polychromatic.
‡ Compared to Clareon PanOptix.
‡‡ Based on bench and vision simulator studies.
§Based on prospective multicenter randomized study at 6 months, significantly more subjects reported not experiencing starburst and glare (p<0.05 n=276).
§§All-implanted analysis set.
¶In response to the IOLSAT questionnaire question 'In the past 7 days, how often did you need to wear eyeglasses to see'?
¶¶Response to the following question on IOLSAT questionnaire (Version 1.0, December 20, 2018) at 6 months post-op "Given your vision today, if you had to do it all over, would you have the same lenses implanted again?"; n=127.
‖ Based on worldwide IOL unit sales of Clareon PanOptix and AcrySof IQ PanOptix through Q1, 2024.
Ω Severity ratings by phakic patients with simulated implant of Clareon PanOptix Pro and Clareon PanOptix using VirtIOL simulator (n=64).
∂ Based in a meta-analysis of 11 unique clinical studies with 580 patients in 10 different countries, including "very bothersome' and "severe" visual disturbances. Clinical studies were performed on the AcrySof IQ PanOptix IOL; AcrySof IQ PanOptix and Clareon PanOptix are optically equivalent.
Expand
References
Alcon data on file, 2025. REF-25218
Alcon data on file, 2024. REF-25221
Alcon data on file, 2015. REF-08546
Krackhardt U, et al: Upper bound on the diffraction efficiency of phase-only fanout elements. Applied Optics; 1992; 31:27-37.; 10. Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston.
Muzychuk, A. Defocus Curve Performance of a Novel Hydrophobic Acrylic Trifocal Intraocular Lens: A prospective, Multicenter Canadian Study. ASCRS Annual Meeting, April 5-8, Boston.
Rayner Professional Website. https://rayner.com/en/iol/trifocal/rayone-trifocal/. Accessed September 2024.
Carones F. New Concept of Light Distribution for Bilateral Trifocal IOL Implantation. AAO. 2022;2022:53.
ZEISS AT LISA tri family. Supplement in Cataract and Refractive Surgery Today (Europe), September 2014.
Zeiss Cataract Insights: Laying the Myth or Reality; Digitalization enhances cataract surgery? Supplement in Ophthalmology Times, Europe; May 22, 2024; https://europe.ophthalmologytimes.com/zeiss-cataract-insight-series?page=1. Accessed September 2024.
Kohnen T, Lapid-Gortzak R, Ramamurthy D, et al. Clinical outcomes after bilateral implantation of a diffractive trifocal intraocular lens: A worldwide pooled analysis of prospective clinical investigations. Clinical Ophthalmology. 2023;Volume 17:155-163. doi:10.2147/opth.s377234.
Alcon data on file, 2024. REF-23958.
Alcon data on file, 2018. REF-01475.
Alcon Vision LLC. Clareon® PanOptix® Trifocal Hydrophobic Acrylic IOL. Product Information. 2021.
Charness N, Dijkstra K, Jastrzembski T, Weaver S, Champion M. Monitor viewing distance for younger and older workers. Proceedings of the Human Factors and Ergonomics Society Annual Meeting. 2008;52(19):1614- 1617. doi:10.1177/154193120805201965
Government of Canada CC for OH and S. CCOHS: Office ergonomics. Canadian Centre for Occupational Health and Safety. April 25, 2023. Accessed May 9, 2023. https://www.ccohs.ca/oshanswers/ergonomics/office/.
Gundersen K, Potvin R. Trifocal intraocular lenses: A comparison of the visual performance and quality of vision provided by two different lens designs. Clinical Ophthalmology. 2017;Volume 11:1081-1087. doi:10.2147/opth.s136164
Kohnen T, Titke C, Böhm M. Trifocal intraocular lens implantation to treat visual demands in various distances following lens removal. American Journal of Ophthalmology. 2016;161. doi:10.1016/j.ajo.2015.09.030
Lwowski C, Pawlowicz K, Petermann K, et al. Visual and patient-reported factors leading to satisfaction after implantation of diffractive extended depth-of-focus and trifocal intraocular lenses. Journal of Cataract and Refractive Surgery. 2022;48(4):421-428. doi:10.1097/j.jcrs.0000000000000780
Alcon data on file, 2024. REF-25903
Alcon data on file, 2024. REF-23554
MarketScope LLC. 2023 IOL Market Report: Global Analysis for 2022 to 2028. St. Louis, MO: MarketScope LLC; 2023.
Clareon® PanOptix® Pro Trifocal Hydrophobic Acrylic IOL Model PXYWT0 2024 Directions for Use.
Zhu D, et al. Rate of complete spectacle independence with a trifocal intraocular lens: A systematic literature review and meta-analysis. Ophthalmology and Therapy. 2023;12(2):1157-1171. doi:10.1007/s40123-023-00657-5.Alcon Vision LLC.
Modi S, Lehmann R, Maxwell A, et al. Visual and patient-reported outcomes of a diffractive trifocal intraocular lens compared with those of a monofocal intraocular lens. Ophthalmology. 2021;128(2):197-207. doi:10.1016/j.ophtha.2020.07.015
Zhu D., Zhang J., et al. Patient-Reported Outcomes of Visual Disturbances with a Trifocal Intraocular Lens: A meta-analysis. Paper presented at: ASCRS Annual Meeting; April 5-8, 2024; Boston.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
5 hours ago
- CNBC
Stock futures rise after S&P 500 notches a fresh record high: Live updates
Traders work on the floor of the New York Stock Exchange on June 27, 2025. NYSE Stock futures rose Sunday evening as investors look to cap a stunning month for stocks. S&P 500 futures and Nasdaq 100 futures each added about 0.1%. Futures tied to the Dow Jones Industrial Average gained 130 points, or 0.3%. The market's swift recovery this month comes as investors continue to monitor the whipsaw of global trade negotiations, which can quickly sway market sentiment and pose an ongoing threat to the strength of this rally. Still, June's surge reflects the exuberance of investors who are relieved that most of the Trump administration's most dire tariff threats haven't been implemented. This month, the S&P 500 is up 4.4%, while the tech-heavy Nasdaq has jumped nearly 6.1%. The Dow, meanwhile, has added about 3.7% month to date. U.S. equities are also coming off a fresh high on Friday, with the S&P 500 reaching a new record in more than four months after ending the session about 0.5% higher at 6,173.07 — overtaking its previous record of 6,147.43. At its low in April, the S&P 500 was down nearly 18% for the year when global trade and tariff tensions rocked the market. The Nasdaq Composite hit an all-time high and closed at a record after adding about 0.5% on Friday, while the Dow Jones Industrial Average rose nearly 1%. Stocks on Friday had pulled back from their session highs after President Donald Trump posted on Truth Social that the U.S. is immediately "terminating ALL discussions on Trade with Canada" in response to Ottawa's decision to move forward with a digital services tax on American tech firms. But earlier in the day, stocks ran up after Commerce Secretary Howard Lutnick said late Thursday that a framework between China and the U.S. on trade had been finalized, and that the Trump administration soon expects to reach deals with 10 major trading partners. Investors remain confident that the strength in price indicates good news for the market moving forward, particularly as opportunities to buy the dip emerge. "The bearish narratives—Middle East conflict, tariffs, soft economic data—keep getting invalidated by the price action," said Ken Mahoney, CEO of Mahoney Asset Management. "Every chance the market has had to break down has failed. Instead, it continues to do what bull markets do best: climb the wall of worry. We think this run can continue, not without volatility to the downside of course."
Business Upturn
6 hours ago
- Business Upturn
DBI Investor News: If You Have Suffered Losses in Designer Brands Inc. (NYSE: DBI), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
NEW YORK, June 29, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Designer Brands Inc. (NYSE: DBI) resulting from allegations that Designer Brands may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Designer Brands securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. The Rosen Law Firm is preparing a class action seeking recovery of investor losses. WHAT TO DO NEXT: To join the prospective class action, go to or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. WHAT IS THIS ABOUT: On June 10, 2025, Designer Brands reported its financial results for the first quarter of 2025. Commenting on the results, Design Brands' CEO stated that '[w]e experienced a soft start to 2025 amid an unpredictable macro environment and deteriorating consumer sentiment.' Further, he stated that '[g]iven the persistent instability and pressure on consumer discretionary spend, we've made the decision to withdraw our 2025 guidance for the time being.' On this news, Designer Brands stock fell 18.2% on June 10, 2025. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. At the time Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
Business Upturn
6 hours ago
- Business Upturn
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Vestis Corporation Investors to Secure Counsel Before Important Deadline in Securities Class Action
NEW YORK, June 29, 2025 (GLOBE NEWSWIRE) — WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Vestis Corporation (NYSE: VSTS) between May 2, 2024 and May 6, 2025, both dates inclusive (the 'Class Period'), of the important August 8, 2025 lead plaintiff deadline. SO WHAT: If you purchased Vestis securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NEXT: To join the Vestis class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than August 8, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. DETAILS OF THE CASE: According to the lawsuit, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Vestis' ability to grow its business; notably that Vestis would be unable to execute on planned strategic initiatives to drive purported improvements to the customer experience and its onboarding efforts in order to drive new customer growth, increased customer retention, and increased revenue from existing customers. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Vestis class action, go to or call Phillip Kim, Esq. at 866-767-3653 or email [email protected] for more information. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: on Twitter: or on Facebook: Attorney Advertising. Prior results do not guarantee a similar outcome. ——————————- Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected]
